Posted on 10/30/20
Erbi Biosystems Closes $3.8 Million Financing
Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT, announced today the closing of a finance round which brings
Posted on 10/30/20
Bristol Myers Squibb: The MyoKardia Acquisition Was Not A Bad Idea
SummaryMYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it.Indeed, . . .
Posted on 10/30/20
Moderna Expects First Look at Coronavirus Vaccine Candidate Data in November
Moderna (NASDAQ:MRNA) expects to take its first interim peek at data from the late-stage clinical trial of its coronavirus vaccine candidate, mRNA-1273, in November. Comments to . . .
Posted on 10/30/20
Alnylam Named a Top Biopharma Employer by Science Magazine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that, for the second year in a row, Science magazine has named . . .
Posted on 10/29/20
Scholar Rock Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a . . .
Posted on 10/29/20
Alexion Reports Third Quarter 2020 Results
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Total revenues in the third quarter were $1,588.7 million, a 26 . . .
Posted on 10/29/20
Elpis Biopharmaceuticals Closes $30 Million Series A
Elpis Biopharmaceuticals today announced the closing of a $30 million Series A financing to propel solid tumor and hematological disease therapeutics through pre-clinical studies
Posted on 10/29/20
Charles River Laboratories Announces Third-Quarter 2020 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2020. For the quarter, revenue was $743.3 million, . . .
Posted on 10/29/20
Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, . . .
Posted on 10/29/20
Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced . . .
Posted on 10/29/20
Agenus R&D Update & Third Quarter Financial Report
LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and . . .
Posted on 10/29/20
Thermo Fisher Scientific Extends Collaboration with Symphogen to Advance Biopharmaceutical Discovery and Development
Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company, Servier, . . .
Posted on 10/29/20
Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting . . .
Posted on 10/29/20
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, . . .
Posted on 10/29/20
Centrexion Therapeutics Raises $40.5 Million
Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing
Posted on 10/29/20
Q32 Bio Closes $60 Million Series B Financing
Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing
Posted on 10/29/20
Amulet Capital Backed Synteract To Be Acquired by Syneos Health
GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners, LP, a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, announced today that it . . .
Posted on 10/29/20
Silver Hill Hospital Names Maggie Smith Director of Patient Access
Silver Hill Hospital, a nationally-recognized leader in the treatment of psychiatric and addiction disorders, named Margaret (Maggie) Smith, M.A. to the newly created role of Director . . .
Posted on 10/28/20
Kevin Hrusovsky to Speak at Precision Medicine Leaders Summit’s Precision Oncology Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer . . .
Posted on 10/28/20
Biogen Aducanumab Committee Danger And Opportunity
Biogen (BIIB) has long been a staple of biotechnology portfolios. It has had about a dozen drugs with commercial sales of late. A share bought in . . .
Posted on 10/28/20
Kevin Hrusovsky to Speak at Precision Medicine Leaders Summit’s Precision Oncology Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer . . .
Posted on 10/27/20
SQZ Biotechnologies Seeks $75 Million IPO
SummarySQZ Biotechnologies intends to raise $75 million in an IPO of its common stock.The firm is researching treatments for HPV+ solid tumors and other conditions using . . .
Posted on 10/27/20
Atea Pharmaceuticals Proposes Terms For $253 Million IPO
SummaryAtea Pharmaceuticals intends to raise $253 million in a U.S. IPO of its common stock.The firm is developing treatments for virus-borne diseases such as Covid-19 and . . .
Posted on 10/26/20
InVivo Therapeutics Closes $15M Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or . . .
Posted on 10/26/20
Akebia Therapeutics to Report Third Quarter 2020 Financial Results
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release . . .
Boston
